Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma

Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma

Doxorubicin is a prototypical inducer of immunogenic cell death (ICD) that sensitizes to subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination fails against glioblastoma, hidden behind the blood–brain barrier (BBB). A recent work delineates a biophysical method for BBB p...

Full description

Saved in:
Bibliographic Details
Main Authors: Jonathan G. Pol, Manuela Lizarralde-Guerrero, Andrea Checcoli, Guido Kroemer
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:OncoImmunology
Subjects:
Blood-brain barrier
cancer immunotherapy
doxorubicin
immune checkpoint inhibitor
ultrasounds
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2024.2385124
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2024.2385124

Similar Items